Trv Gp Vi LLC Purchases New Holdings in Seaport Therapeutics, Inc. $SPTX

Trv Gp Vi LLC bought a new position in shares of Seaport Therapeutics, Inc. (NASDAQ:SPTX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,061,222 shares of the company’s stock, valued at approximately $44,769,742,000. Seaport Therapeutics comprises approximately 19.3% of Trv Gp Vi LLC’s investment portfolio, making the stock its 2nd biggest holding. Trv Gp Vi LLC owned 3.85% of Seaport Therapeutics at the end of the most recent reporting period.

Seaport Therapeutics Stock Down 1.8%

Shares of NASDAQ:SPTX opened at $23.97 on Wednesday. The company’s 50 day simple moving average is $20.65. Seaport Therapeutics, Inc. has a 1 year low of $14.85 and a 1 year high of $25.07. The stock has a market cap of $1.28 billion and a price-to-earnings ratio of -1.98.

Seaport Therapeutics (NASDAQ:SPTX) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($1.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($1.07). As a group, analysts forecast that Seaport Therapeutics, Inc. will post -4.6 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Seaport Research Partners set a $50.00 target price on shares of Seaport Therapeutics in a report on Wednesday, July 15th. Weiss Ratings started coverage on shares of Seaport Therapeutics in a research note on Tuesday, August 11th. They set a “sell (d+)” rating on the stock. Leerink Partners started coverage on shares of Seaport Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $35.00 price objective on the stock. Citigroup began coverage on Seaport Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $35.00 target price for the company. Finally, BNP Paribas Exane cut Seaport Therapeutics to a “market perform” rating in a research report on Tuesday, May 26th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $38.40.

Insider Buying and Selling at Seaport Therapeutics

In other news, Director Robert J. Hombach acquired 13,000 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $18.14 per share, with a total value of $235,820.00. Following the completion of the acquisition, the director owned 13,000 shares of the company’s stock, valued at $235,820. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Seaport Therapeutics Profile

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.